Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users

Department of Molecular Microbiology and Immunology, Johns Hopkins University, Baltimore, Maryland, United States
JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 01/1998; 279(1):35-40. DOI: 10.1001/jama.279.1.35
Source: PubMed


Plasma human immunodeficiency virus type 1 (HIV-1) viral load and CD4+ cell count are used to predict prognosis of persons infected with HIV. However, whether combining these markers improves prognostic accuracy and whether they predict prognosis for injection drug users (IDUs) and nonwhite persons infected with HIV has not been extensively investigated.
To evaluate plasma viral load and CD4+ cell count as prognostic indicators for the acquired immunodeficiency syndrome (AIDS) and infectious disease deaths.
Cohort study initiated in 1988 and 1989 with follow-up for up to 7.9 years.
Injection drug users infected with HIV recruited from the community in Baltimore, Md.
Plasma HIV-1 RNA and CD4+ cell count measured at baseline compared with time to first clinical AIDS diagnosis and death due to an infectious disease.
Of 522 subjects, 96% were African American, 80% were male, 96% injected drugs within the past 6 months, and the median age was 33 years. A total of 146 cases of AIDS and 119 infectious disease deaths were seen during a median follow-up period of 6.4 years. Time-fixed baseline levels of viral load and CD4+ cell count were independent predictors of progression to AIDS and infectious disease deaths, but in proportional hazards models, viral load had better predictive value than CD4+ cell count. Kaplan-Meier analysis of time to AIDS and to infectious disease deaths by viral load (<500, 500-9999, 10000-29 999, > or =30000 copies/mL) at 3 levels of CD4+ cell count (<0.20, 0.20-0.49, and > or =0.50x10(9)/L [<200,200-499, and > or =500/microL]) was reduced to a 5-stage classification scheme using a backward stepwise regression procedure. The 5-year cumulative probabilities for AIDS and infectious disease deaths ranged from 0% and 0%, respectively, for group I (viral load, <500 copies/mL; CD4+ cell count, 0.50x10(9)/L) to 81.2% and 76.1% respectively, for group V (viral load, > or =10000 copies/mL; CD4+ cell count, 0.20x10(9)/L).
In this study, plasma HIV-1 viral load independently and in combination with CD4+ cell count measurements provided powerful prognostic information for progression to AIDS and death caused by infectious disease in a population of predominantly African American IDUs. Combining categories of both markers provided a simple method for prognostically staging HIV disease.

Download full-text


Available from: David Vlahov,
    • "The amount of CD4 lymphocyte cells per milliliter and/or the quantity of RNA-HIV-1 copies per milliliter (viral load) are surrogate markers of HIV disease progression. It is known that HIV-positive patients with CD4 lymphocyte cells counts less than 200 per milliliter are severely immune depressed and HIV-positive patients with a viral load greater than 10,000 copies per milliliter show an active viremia.[67] The CD4 cell count and viral load have been used lately as the most important laboratory parameters to evaluate the evolution of the disease.[8] "
    [Show abstract] [Hide abstract]
    ABSTRACT: From the onset of the human immunodeficiency virus (HIV) epidemic over 20 years ago (since the appearance of the first cases of contamination by the HIV virus in the 1980s), more than 60 million people have become infected and more than 20 million people have died. An estimated 15,000 new infections occur each day, with more than 95% of these in developing countries. The distinctive characteristic in the pathogenesis of HIV/acquired immunodeficiency syndrome is that the primary target cell for HIV is immune cells bearing the CD4 marker at their surface, and the CD4 cell count and viral load have been used lately as the most important laboratory parameters to evaluate the evolution of the disease. Oral lesions are common (30-80%) in patients infected by the HIV virus and may indicate an impairment in the patient's general health status and, consequently, a poor prognosis. Oral manifestations can suggest decreased cluster-differentiated (CD4+) T cell count and increased viral load, which might also aid in diagnosis, progression, and prognosis of the disease. At the tertiary level of oral care, a dentist should be available to make definitive diagnoses of oral lesions and provide professional oral services such as prophylaxis, restorations, biopsies, and the prescription of appropriate medication.
    The Journal of Natural Science, Biology and Medicine 07/2011; 2(2):145-50. DOI:10.4103/0976-9668.92316
  • Source
    • "HIV primarily targets CD4+ T-lymphocytes, and recent studies have shown that during primary HIV infection, HIV viral replication in CD4+ T-lymphocytes in gut-associated lymphoid tissue (GALT) results in significant CD4+ Tlymphocyte depletion [1] [2]. Chronic HIV infection affects both quantitative and qualitative function of CD4+ Tlymphocytes , and disease progression results from continuous depletion of these cells with a concomitant increase in risk for opportunistic infections, acquired immune deficiency syndrome (AIDS), and death [3] [4] [5]. Given the central role of CD4+ T-lymphocytes in HIV pathogenesis, CD4+ Tlymphocyte determination during the course of HIV disease is one of the most reliable predictors of prognosis [6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. CD4+ T-lymphocyte monitoring is not routinely available in most resource-limited settings. We investigated predictors of time to CD4+ T-lymphocyte recovery in HIV-infected children on highly active antiretroviral (HAART) at Korle-Bu Teaching Hospital, Ghana. Methods. Time to CD4+ T-lymphocyte recovery was defined as achieving percent CD4+ T-lymphocytes of 25%. We used Cox proportional hazard models for identifying significant predictor variables. Results. Of the 233 children with complete CD4+ T-lymphocyte data, the mean age at HAART initiation was 5.5 (SD = 3.1) years. The median recovery time was 60 weeks (95% CL: 55-65). Evidence at baseline of severe suppression in CD4+ T-lymphocyte count adjusted for age, age at HAART initiation, gender, and having parents alive were statistically significant in predicting time to CD4+ T-lymphocyte recovery. Conclusions. A targeted approach based on predictors of CD4+ T-lymphocyte recovery can be a viable and cost-effective way of monitoring HAART in HIV-infected children in resource-limited settings.
    AIDS research and treatment 05/2011; 2011(2):896040. DOI:10.1155/2011/896040
  • Source
    • "The hallmark of HIV infection is progressive CD4+ T cell depletion leading to an increased risk for the development of opportunistic infections, acquired immune deficiency syndrome (AIDS), and death [8] [9] [10]. The advent of HAART "
    [Show abstract] [Hide abstract]
    ABSTRACT: Twenty-nine years into the HIV epidemic, several advances have been made; however, there remain several challenges particularly with pediatric HIV in resource-limited countries. The obstacles facing pediatric antiretroviral therapy (ART) delivery in resource-limited countries are multifaceted: lack of health care infrastructure, limited availability of pediatric drug formulations, lack of early HIV diagnostic and monitoring techniques, limited manpower with expertise in pediatric HIV care, limited donor funding, and competing public health priorities with limited health care budget. In this paper, the challenges with various ART monitoring tools in resource-limited countries are discussed. Noninvasive (e.g., patient, clinical events outcome, and adherence) and invasive (e.g., immunologic and virologic) monitoring tools are discussed. Several cheap and technically less complex laboratory tests for monitoring are becoming available. Funding agencies and country programs should invest in validating the use of current technologies to optimize pediatric HIV care in resource-limited countries.
    AIDS research and treatment 01/2011; 2011(2090-1240):280901. DOI:10.1155/2011/280901
Show more